Courtagen Developing Assay for Avaxia's Radiation Therapy | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein diagnostic firm Courtagen said today that it has entered into a collaboration with Avaxia Biologics to create an assay for use in developing an oral antibody therapy to mitigate the gastrointestinal damage caused by radiation exposure.

The therapy being developed is for use in radiation exposure from a nuclear incident.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.